Protalix BioTherapeutics, Inc. 4
4 · Protalix BioTherapeutics, Inc. · Filed May 7, 2015
Insider Transaction Report
Form 4
Shaaltiel Yoseph
DirectorExecutive VP, R&D
Transactions
- Award
Stock Options (Right to Buy)
2015-03-23+275,000→ 275,000 totalExercise: $1.72Exp: 2025-03-23→ Common Stock (275,000 underlying)
Footnotes (2)
- [F1]25% of the shares of common stock underlying the stock options shall vest on the first one-year anniversary of the date of grant and the remaining 75% of the shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing on such anniversary. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended.
- [F2]Does not include options to purchase 122,162 shares of common stock at an exercise price equal to $0.001 per share that expire on June 30, 2016; options to purchase 263,728 shares of common stock at an exercise price equal to $5.00 per share that expire on February 7, 2018; options to purchase 50,000 shares of common stock at an exercise price equal to $2.65 per share that expire on February 25, 2019; and options to purchase 145,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020.